Heron Therapeutics(HRTX) - 2022 Q4 - Earnings Call Presentation

Heron Pipeline of 4 Approved Products With $107.7 million in | --- | --- | --- | --- | |------------|------------------------------------------------------------------|------------------------------------|----------------------------------------------------------------| | | ZYNRELEF® (bupivacaine and meloxicam) extended-release solution | sNDA#2 PDUFA Goal October 23, 2023 | US FDA Approved for postsurgical analgesia for up to 72 hours* | | Acute Care | APONVIE™ (aprepitant) injectable emulsion | Launched M ...